Effectiveness of SPECT/CT imaging for sentinel node biopsy staging of primary cutaneous melanoma and patient outcomes by Moncrieff, Marc et al.
ORIGINAL ARTICLE – MELANOMA
Effectiveness of SPECT/CT Imaging for Sentinel Node Biopsy
Staging of Primary Cutaneous Melanoma and Patient Outcomes
Marc Moncrieff, MD FRCS(Plast.)1,3 , Sarah Pywell, MBBS, MRCS1, Andrew Snelling, FRCS(Plast.)1,
Matthew Gray, PhD2, David Newman, FRCR2, Clare Beadsmoore, FRCP2, Davina Pawaroo, FRCR2, and
Martin Heaton, MD FRCS(Plast.)1
1Department of Plastic & Reconstructive Surgery, Norfolk & Norwich University Hospital NHS Trust, Norwich, UK;
2Department of Nuclear Medicine, Norfolk and Norwich University Hospitals NHS Foundation, Norwich, UK; 3Norwich
Medical School, University of East Anglia, Norwich, UK
ABSTRACT
Purpose. Coregistered SPECT/CT can improve accuracy
of sentinel node biopsy (SNB) for staging melanoma. This
benefit has implications for pathology services and surgical
practice with increased diagnostic and surgical workload.
The purpose of this study was to investigate the effec-
tiveness of SPECT/CT imaging.
Methods. SNB data were collected over a 10-year period.
Preoperative SLN mapping was performed by using planar
lymphoscintigraphy (LSG) for all patients (n = 1522) and
after October 2015, patients underwent a second co-regis-
tered SPECT/CT scan (n = 559). The patients were
stratified according to the imaging protocol. The number of
nodes and nodal basins were assessed. The reasons for
cancellation also were assessed.
Results. A total of 95% (1446/1522) of patients underwent
a successful SNB procedure. Significantly more sentinel
nodes were identified by the SPECT/CT protocol (3 vs. 2;
p\ 0.0001). More patients were cancelled in the SPECT/
CT cohort (9.3% vs. 2.5%; p \ 0.0001). Head & neck,
lower limb, and AJCC IB primaries were significantly less
likely to proceed to SNB. SPECT/CT identified
significantly more positive SNBs (20.9% vs. 16.5%; p =
0.038). SPECT/CT imaging was associated with improved
disease-free (hazard ratio [HR] = 0.74; 95% confidence
interval [CI]: 0.54–1.0); p = 0.048) and disease-specific
survival (HR = 0.48; 95% CI: 0.3–0.78; p = 0.003). Patients
who did not proceed to SNB had a significantly increased
nodal relapse rate (23.5% vs. 6.8%; HR = 3.4; 95% CI:
1.9–6.2; p\ 0.0001) compared with those who underwent
SNB.
Conclusions. This large cohort study confirms the
increased accuracy of SPECT/CT for identifying SLN
metastases, which would appear to have a significant
therapeutic benefit, although an increased risk of cancel-
lation of the SNB procedure on the day of surgery.
Primary cutaneous melanoma readily metastasises via
the draining lymphatic system to the regional lymph nodes.
Unlike other cancers, the lymphatic drainage pattern of the
primary tumour cannot be easily predicted based on its
anatomical location, making elective lymph node dissec-
tion an unreliable and ineffective treatment strategy.
Sentinel node biopsy (SNB) is a technique developed to
identify the lymphatic drainage of the primary tumour and
to stage the regional lymph nodes to identify patients in
need of further treatment.1 Since its development, SNB has
evolved to become the standard of care for primary cuta-
neous melanoma and is incorporated in the current AJCC
classification system.2
Accurate preoperative lymphoscintigraphy (LSG) is
essential for successfully performing SNB.3 However,
there is a recognised false-negative rate associated with the
technique,4 particularly in the head and neck region, and
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data from Sydney suggest that failure to visualise the SN
accurately is contributory to the false-negative rate.5 The
introduction of coregistered single-photon emission com-
puted tomography with integrated computed tomography
(SPECT/CT) has greatly improved the accuracy of locali-
sation of the sentinel lymph node(s) (SLN) prior for
primary cutaneous melanoma.6–11 At a national SNB
consensus meeting, concerns were raised by the patholo-
gists that more SLNs were being harvested since the
introduction for SPECT/CT imaging, thereby impacting on
workload and throughput.12 Similarly, concerns were
raised by the surgeons that the increasing accuracy of SLN
identification, whilst generally considered a positive ben-
efit, was associated also with increasing surgical morbidity
and an increasing number of SNB procedures cancelled
preoperatively. The purpose of this study was to investigate
the effectiveness of SPECT/CT imaging for SNB staging of
cutaneous melanoma in a large cohort treated at an aca-
demic, tertiary referral cancer centre.
METHODS
This is a single-centre, retrospective, cohort study based
on a prospectively collected institutional database. Central
regulatory approval for this study was granted by the UK
NHS Health Research Authority (IRAS ID: 234471). Data
were collected over a 10-year period, from 2009 to 2019,
inclusive. The primary inclusion criteria were all adult
patients (aged 18 years or older) with primary cutaneous
melanoma AJCC T-stage pT1b-pT4b scheduled for wide
excision and SNB at our regional cancer centre. All pri-
mary melanoma specimens and their associated wide
excision and SNB specimens were subject to centralised
pathology review as part of their standard of care. Patients
with mucosal and/or genital melanomas, in addition to
melanocytic tumours of unknown malignant potential
(‘‘mel-TUMP’’) were excluded. Standard patient demo-
graphic data and primary tumour characteristics were
recorded.
The primary outcome measures were the rates of suc-
cessful preoperative sentinel node localisation and
successful completion of the planned sentinel node biopsy
compared between the two planning protocols. Subgroup
analyses included demographics, tumour AJCC stage, and
location. The number of sentinel nodes and their nodal
basins identified by the imaging protocols were recorded.
Second echelon nodes, identified by the reporting nuclear
medicine clinician by comparing the early-phase and
delayed imaging, were not included in these measurements.
The reasons for cancellation also were assessed to see if
there was a pattern that could be attributed to either
imaging modality. The number of nodes harvested at the
SNB procedure were not recorded, because this is a
recognised weak correlation with the accuracy of the
imaging protocol and was not the outcome of interest in
this study.13,14 Survival outcomes data were collected from
patient follow-up which included disease-free survival
(DFS), nodal relapse-free survival (NRFS), disease-specific
survival (DSS), and overall (OS) survival according to
standard FDA criteria.15 DFS was subclassified as local
(including local, satellite, and in transit recurrences),
regional (within draining nodal field), or distant recur-
rences and were censored at the date of first diagnosis on
the histopathology and/or radiology report. In the case of
multiple site recurrence, DFS was recorded based on the
first instance and highest stage at that time, according to the
‘‘first/worst’’ principle.
Procedure/Technique
All SLNB procedures were performed at a single tertiary
referral cancer centre according to a standardised interna-
tional protocol using a dual localisation technique.3
Patients underwent a preoperative sentinel localisation and
mapping using 20-40 MBq technetium-labelled nanocol-
loid (NanoCollTM) injected intradermally directly adjacent
to the centre of the melanoma scar. In all cases, patients
were scanned sequentially using planar lymphoscintigra-
phy each minute for 10 minutes and then a separate delayed
planar LSG scan was performed at 1 hour. From October
19, 2015, the patient underwent a second SPECT/CT
(Siemens, Germany) scan, which coregistered the gamma
signal to a whole body CT. For all patients, LSG images
were available to the reporting nuclear medicine physician
and the operating surgeon. After October 2015, both clin-
icians also had the additional information from the co-
registered SPECT/CT. For the purpose of this study,
patients were divided into two cohorts: those who had had
only planar LSG imaging (pre October 19, 2015) and those
who had both LSG and SPECT/CT. Surgery was performed
in a standardised manner according to our unit protocol,
using a dual-localisation technique of intraoperative
injection of Patent Blue dye (Geurbet, France) and radi-
olocalisation using a Navigator 2.0 gamma probe (Dilon
Technologies, Virginia, USA). Further technical details of
our protocol have been described elsewhere.16
Statistical Analysis
Pseudoanonymised data were analysed using Jamovi
software (Version 1.6, Sydney, Australia https://www.jam
ovi.org) and R-Studio (version 1.3.1093, Boston, MA),
both running R-language (version 3.6, https://cran.r-projec
t.org/). Patients characteristics and histopathological
parameters were summarised using descriptive statistics
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stratified by scan type. Differences between groups were
tested using Kruskal-Wallis test as appropriate for contin-
uous variables and Pearson chi-squared tests for categorical
variables. Univariable and multivariable Cox proportional
hazard regressions were performed to identify factors that
are associated to either survival outcomes. Survival out-
comes data were also analysed using the Kaplan-Meier log-
rank test.
RESULTS
A total of 1522 primary cutaneous melanoma patients
were identified from our prospective institutional database.
Table 1 summarises the cohorts and highlights the outcome
variables stratified by preoperative imaging modality (LSG
versus SPECT/CT). The LSG group comprised 963
patients and the SPECT/CT group 559 patients. The
table demonstrates that both groups were matched for age,
site of primary, Breslow thickness, AJCC stage, incidence
of ulceration, and microsatellites. There was significantly
greater proportion of men in the SPECT/CT cohort (56.4%
vs. 51.0%; p = 0.043)
Preoperative Sentinel Node Identification
Table 1 reveals that the median number of nodal basins
identified was one (interquartile range [IQR] 1–2) for both
imaging protocols. However, there was a significantly
increased number of sentinel nodes identified by the
SPECT/CT regimen compared with the LSG regimen (3 vs.
2; p\ 0.0001). The analysis also showed a significantly
increased sentinel node positivity rate in the SPECT/CT
TABLE 1 Patient
demographics, tumour factors,
imaging, and patient outcomes
stratified by imaging modality
N LSG SPECT/CT Test statistic
963 559
Age (yr) 1522 51 (63–71) 53 (65–72) F(1,1520) = 3.17, p = 0.075c
Gender: M 1522 51.0% (491/963) 56.4% (315/559) v2(1) = 4.09, p = 0.043
Primary site 1522 v2(3) = 1.17, p = 0.761
Torso 37.9% (365/963) 39.0% (218/559)
Head and neck 15.9% (153/963) 16.6% (93/559)
Upper extremity 20.9% (201/963) 18.6% (104/559)
Lower extremity 25.3% (244/963) 25.8% (144/559)
Breslow thickness (mm) 1,522 1.10 (1.70–2.90) 1.20 (1.70-2.98) F(1,1520) = 0.54, p = 0.461c
Ulceration: Yes 1,522 24.1% (232/963) 24.0% (134/559) v2(1) = 0.00, p = 0.958
Microsatellites: yes 1522 3.9% (38/963) 5.2% (29/559) v2(1) = 1.30, p = 0.255
AJCC stagea 1522 v2(6) = 11.23, p = 0.081
IB 54.2% (522/963) 53.5% (299/559)
IIA 20.8% (200/963) 19.1% (107/559)
IIB 12.6% (121/963) 14.0% (78/559)
IIC 8.5% (82/963) 8.2% (46/559)
IIIB 2.0% (19/963) 2.5% (14/559)
IIIC 2.0% (19/963) 2.7% (15/559)
Basin count 1522 1 (1–2) 1 (1–2) F(1,1520) = 3.63, p = 0.057c
Node count 1522 2 (1–3) 2 (3–4) F(1,1520) = 66.54, p = 0.000c
SN status: positive 1446 16.5% (155/939) 20.9% (106/507) v2(1) = 4.31, p = 0.038
Site of first recurrenceb 1522 v2(3) = 47.94, p = 0.001
None 76.9% (741/963) 88.2% (493/559)
Local 7.0% (67/963) 2.5% (14/559)
Regional 3.7% (36/963) 5.4% (30/559)
Distant 12.4% (119/963) 3.9% (22/559)
SNB performed?: no 1522 2.5% (24/963) 9.3% (52/559) v2(1) = 34.58, p = 0.001
N number of nonmissing values; SN sentinel node; SNB sentinel node biopsy; LSG planar lym-
phoscintigraphy; SPECT/CT single positron emission computerised tomography with coregistered
computerised tomography
aAJCC stage, 8th edition of the primary before SNB result
bBased on the first worst recurrence (see text)
cKruskal-Wallis test
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cohort (20.9% vs. 16.5%; p = 0.048). Multivariable anal-
ysis stratified for age, gender, Breslow thickness, ulceration
and microsatellites identified the imaging modality as a
significant independent predictor of sentinel node status
(odds ratio 1.34 (range 1.0–1.78); p = 0.046).
Effectiveness
SNB was performed in 95.0% (1446/1522) of all
patients scheduled for the procedure. At least one sentinel
node was identified and biopsied at operation in all but one
patient (intraoperative failure rate = 0.6%). Table 2 shows
that there was a significantly increased SNB cancellation
rate in the SPECT/CT group compared with the LSG group
(9.3% vs. 2.5%; p \ 0.0001). The SPECT/CT group
accounted for 68.4% (52/76) of all the SNB cancellations.
Primary tumours located in the head and neck region or on
lower extremity were more likely to be cancelled (38.2%
and 35.5%, respectively) compared with those located on
the upper limb or torso (9.2% and 17.1%, respectively; p\
0.0001). A significantly greater proportion of AJCC IB
patients (T-Stage pT1b-pT2a) were cancelled in the
SPECT/CT cohort (5.9% vs. 0.7%; Chi-square test for
trend: p = 0.043). When the cancellation cohort were
stratified by imaging modality, SPECT/CT imaging was
associated with younger age (64 vs. 72 years, p = 0.023),
TABLE 2 Subgroup analysis
of the cohort where SNB was
not performed, stratified by
imaging modality
N LSG SPECT_CT Test statistic
24 52
SNB performed: no 1522 2.5% (24/963) 9.3% (52/559) v2(1) = 34.58, p = 0.000
Reason for cancellation 76 v2(3) = 13.76, p = 0.003
Too many nodes 29.2% (7/24) 65.4% (34/52)
No tracer migration 50% (12/24) 17.3 (9/52)
Nodal location 0% (0/24) 7.7% (4/52)
Other 20.8% (5/24) 9.6% (5/52)
Gender: M 76 45.8% (11/24) 50% (26/52) v2(1) = 0.114, p = 0.736
AGE 76 72 (63–77) 64 (56–71) F(1,74) = 5.15, p = 0.023
Primary site v2(3) = 0.929, p = 0.819
Torso 16.7% (4/24) 17.3% (9/52)
Head and neck 41.7% (10/24) 36.5% (19/52)
Upper extremity 12.5% (3/24) 7.7% (4/52)
Lower extremity 29.2% (7/24) 38.8% (20/52)
Breslow thickness (mm) 76 2.8 (1.6–5.1) 1.3 (0.9-3.3) F(1,74) = 5.82, p = 0.016
Ulceration: yes 76 41.7% (10/24) 21.2% (11/52) v2(1) = 3.46, p = 0.063
Microsatellites: yes 76 4.2% (1/24) 7.7% (4/52) v2(1) = 0.332, p = 0.564
AJCC stagea 76, 1522 2.5% (24/963) 9.3% (52/559) v2(5) = 34.58, p = 0.043
IB 29.2% (7/24) 63.5% (33/52)
0.7% (7/963) 5.9% (33/559)
IIA 16.7% (4/24) 5.8% (3/52)
0.4% (4/963) 0.5% (3/559)
IIB 16.7% (4/24) 9.6% (5/52)
0.4% (4/963) 0.9% (5/559)
IIC 33.3% (8/24) 13.5% (7/52)
0.8% (8/963) 1.3% (7/559)
IIIB 4.2% (1/24) 1.9% (1/52)
0.1% (1/963) 0.2% (1/559)
IIIC 0% (0/24) 5.8% (3/52)
0% (0/963) 0.5% (3/559)
Basin count 76 1 (0–1) 2 (1-2) F(1,74) = 8.2, p = 0.004
Node count 76 1 (0–5) 6 (4-6) F(1,74) = 11.4, p = 0.000
N number of nonmissing values
1Kruskal-Wallis test
2Pearson test
aAJCC stage, 8th edition of the primary before SNB result
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thinner tumours (median Breslow thickness 1.3 mm vs. 2.8
mm, p = 0.16), and higher basin (2 vs. 1, p = 0.004) and
node (6 vs. 1, p\0.001) counts. The documented reasons
for SNB cancellation were more likely to be due to too
many nodes identified on the scan or inaccessible nodal
location in the SPECT/CT group, whereas tracer migration
failure was the most common reason for the LSG group
(Chi-square test for trend; p = 0.003). Other reasons for
canceling the SNB procedure included disease progression
detected at time of imaging (including satellites at the
primary site or unambiguous distant metastases seen on the
SPECT/CT scan: n = 5), cancellation of procedure by
patient request (n = 3), patient failure to attend (n = 2), and
severe allergic reaction (n = 1). Cancellation was not
associated with gender of the patient, nor the presence of
microsatellites.
Survival Outcome
The median follow-up period was 85 months for the
LSG group and 32 months for the SPECT/CT group. There
were 288 recurrences and 155 melanoma deaths in total
during the study period. Univariable analysis showed that
patients who did not undergo sentinel node biopsy had a
significantly worse 5-year nodal relapse-free survival
(76.5% vs. 93.2%; HR = 3.4 (95% CI: 1.9–6.2); p \
0.0001; Fig. 1), but this did not translate into a significantly
worse DSS during that period (HR = 0.5; p = 0.242). An
intention to treat analysis of the cohort demonstrated a
significantly increased risk of nodal relapse in the SPECT/
CT group (HR = 1.55 (95% CI: 1.0–2.4); p = 0.049) and
reduced risk of death from melanoma (HR = 0.60 (95% CI:
0.38–0.95); p = 0.03) compared with the LSG group but no
significant differences in DFS.
Patients who did not proceed to SNB were excluded
from the remaining analysis to test the effect of the
imaging modalities on patient outcome. Univariable anal-
ysis showed no significant difference in DFS (HR = 0.82
(95% CI: 0.61–1.11); p = 0.21) but a significant difference
in DSS (HR = 0.60 (95% CI: 0.37–0.96); p = 0.031) with
an absolute survival difference of 3.4% at 3 years, in
favour of the SPECT/CT group. The nodal relapse rates
were the same for both cohorts, when SNB was performed
(HR = 1.34 (95% CI: 0.83–2.16); p = 0.22). Multivariable
analysis, stratifying for age, gender, Breslow thickness,
ulceration and microsatellites, primary site location, and
sentinel node status revealed that the imaging modality
used was a significant independent predictor of DFS (HR =
0.74 (95% CI: 0.54–1.0); p = 0.048) and DSS (HR = 0.48
(95% CI: 0.3–0.78); p = 0.003) but not of nodal relapse-
free survival (HR = 1.26 (95% CI: 0.78–2.04); p =
0.34).These findings are represented graphically in the odds
ratio plots (Fig. 2a-c).
DISCUSSION
The prognostic significance of SN status for primary
cutaneous melanoma is undoubted.2,17 Furthermore, the
MSLT-1 data indicated that a nodal micrometastasis
without intervention is likely to progress to palpable dis-
ease and that the act of removing the lymph nodes at the
time of SNB may prevent further nodal progression and
relapse.17 However, the main role of sentinel node biopsy
has shifted from identifying patients who require surgical
intervention, namely regional lymphadenectomy, to accu-
rately identifying patients who are eligible for adjuvant
systemic therapy.12,18 The dataset that underpinned the
latest AJCC classification system for melanoma, confirmed
the primacy of SNB for staging primary cutaneous mela-
noma.2 In addition, maturing data from large phase III
clinical trials are suggesting a long-term survival benefit
from adjuvant systemic therapy.19,20 Accordingly, the
accurate identification of SLNs has taken on an additional
significance in the past few years.
Survival curves for SLN_PERFORMED
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FIG. 1 Kaplan-Meier cumulative hazard plots comparing nodal
relapse-free survival in patients who underwent SNB compared with
those whose procedures were cancelled
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The EANM guidelines suggest that SPECT/CT is
preferable on the basis that it improves the localization of
SLNs and reduces misinterpretation of images, because
they are three-dimensional and have better contrast and
spatial resolution.21 It is suggested that this is particularly
important in the head and neck region.22 The EANM
guidelines also suggest that SPECT/CT is highly
recommended for the groin and axillary areas, because
‘‘…it facilitates the detection of in-transit nodes and
aberrant lymphatic drainage stasis in lymph vessels and
consequently facilitates the surgical procedure.’’ A large,
prospective, multicentre trial, the International Atomic
Energy Agency Sentinel Node Trial, demonstrated that
SPECT/CT had modified the surgical approach in 37% of























































































FIG. 2 a Disease-free survival.
b Disease-specific survival
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patients with melanoma, with greatest improvement in
accuracy seen in the head and neck, and truncal regions.23
A recent meta-analysis demonstrated a higher overall SLN
detection rate and proportion of patients with additional
SLNs.24 Another study highlighted the health economic
benefit of this approach.25 Our data are consistent with the
previous literature in that we found a significantly
increased number of SLNs and were identified by SPECT/
CT compared with LSG (median 3 vs. 2; p \ 0.0001)
(Table 1). Furthermore, a near-significant trend of an
increase in the number of identified nodal basins also was
found (p\ 0.06) (Table 1).
Perioperative Outcomes and Effectiveness
Whilst our data have confirmed previous findings that
the additional information provided by SPECT/CT imaging
of SLNs increases the opportunity for perioperative deci-
sion-making, but perhaps not always in the positive manner
that previous publications have suggested.21 Our data have
shown that the tracer agent migration failure rate has been
consistent across the study period (1–1.5%), regardless of
the imaging technique employed. However, there was a
significantly increased number of preoperative cancella-
tions of the SNB procedure in the SPECT/CT group
compared with the LSG group (9.3% vs. 2.5%; p = 0.003).
Closer inspection of Table 2 highlights that the two main
reasons were too many nodes were identified or the relative
surgical inaccessibility of the SLNs located on the scan. It
is clear that these decisions are subjectively made, based on
both the patients’ and surgeons’ evaluations of the per-
ceived risk of missing the diagnostic opportunity from not
undertaking the SNB versus the benefit from avoiding the
potential morbidity of the procedure and, secondarily, the
opportunity to avoid a general anaesthetic if a wide exci-
sion alone is performed instead. Whilst these decisions
were subjective, no gender bias was detected in our
analysis.
Further inspection of the data provides clues to the main
factors that influence that decision-making process. In the
SPECT/CT group, cancellations of the SNB procedure
were significantly more common in the AJCC IB group
(pT1b-pT2a), where the risk of sentinel node positivity is
relatively low (*5–10%). In addition, cancellations were
significantly more common in the head and neck and lower
extremity regions. Whilst the granular details of the deci-
sion-making process are unavailable in this study, it is
reasonable to assume that the reasons for cancellation are
due to the anatomical idiosyncrasies of both these regions.
In the head and neck, the lymphatic drainage is usually
complex, and often bilateral.26 The combined risks of
potential injury to superficial cranial nerves, drainage to
multiple levels in the neck occasionally necessitating
several incisions for access, and the reduced accuracy of
SLN localisation in general make SNB relatively undesir-
able and hazardous in this region.4,26 Similarly, lower-
extremity melanomas routinely drain to the pelvis, which
can be challenging for the surgeon to access to perform a
successful procedure.26 Furthermore, dual drainage to the
groin and pelvis significantly increases the risk of postop-
erative lymphoedema, which is a major quality of life and
survivorship issue for melanoma patients, where the
majority of patients are sentinel node-negative and nearly
half of the patients are younger than aged 60 years.27,28
Survival Outcomes
The MSLT-1 study is rightly described as a landmark
trial, which confirmed the prognostic and therapeutic utility
of SNB for primary cutaneous melanoma.17,29 Our data are
aligned with several of the main outcomes of the study,
including a reduced disease-specific survival for the SNB-
positive patients and a reduced regional control rate in the
patients who did not undergo sentinel node biopsy. Our
data showed an increased SNB-positive rate in the SPECT/
CT cohort (20.9% vs. 16.5%; p = 0.048). The MSLT-1
study data made a highly compelling argument for a sur-
vival benefit for a small group of patients undergoing SNB
who have their focus of micrometastatic disease excised.
Our data showed that, despite the increased incidence of
sentinel node positivity, the SPECT/CT cohort had a sig-
nificantly improved disease-specific survival compared
with the LSG cohort. Whilst these data need to be inter-
preted with caution, one possible explanation for the
observed outcome is the more accurate identification of
sentinel nodes containing the metastatic focus and their
subsequent removal afforded by the SPECT/CT imaging
regimen.
A potentially counterintuitive finding was the signifi-
cantly increased risk of nodal relapse in the SPECT/CT
group from the intention to treat analysis (HR = 1.55 (95%
CI: 1.0–2.4); p = 0.049), despite the improved accuracy of
the technique and the increased SNB positivity rate. The
likely explanation is the effect of the significantly increased
risk of perioperative cancellation of the SNB in this cohort
compared with the LSG cohort, given the targeted sub-
group analysis showed no difference in this endpoint when
the cancelled patients were excluded. We believe this is a
hitherto unreported negative consequence of the preferen-
tial use of SPECT/CT imaging and is an important point to
consider when patients are being counselled for their sur-
gery, particularly when considering cancelling the SNB
procedure. It also is important to note, however, that this
did not translate into worse DSS, in contrast to the results
of the MSLT-1 study.17
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Study Limitations
We acknowledge several limitations of our study. Our
data are limited to a single centre, albeit that it is one of the
largest cohorts to report on this subject. Furthermore, the
follow-up is relatively short and is therefore unable to
detect the effects of late recurrences beyond 5 years, which
are common in cutaneous melanoma.30 The major limita-
tion of the study is that the cohorts are not
contemporaneous. During the period 2009–2015, when
planar LSG was the only imaging modality available,
patients were routinely offered completion lymph node
dissection (CLND) for a positive SNB, although our centre
was actively recruiting to the MSLT-2 study,31 and it was
therefore not universally applied. Subsequently, the results
of that study confirmed that CLND was not effective for
SNB positive patients and no longer offered as a standard
of care for our patients. From late 2016 onwards, effective
systemic therapy became available for patients with
recurrences or high-risk disease. Accordingly, it is chal-
lenging to draw major conclusions and the comparative
DFS and DSS outcomes between the two cohorts should be
interpreted with caution, although the two cohorts were
otherwise well-matched in terms of patient demographics
and tumour characteristics otherwise, which potentially
limits the effects of these biases.
CONCLUSIONS
This large cohort study confirms the increased accuracy
of SPECT/CT for identifying SLN metastases in cutaneous
melanoma, which is associated with a significant thera-
peutic benefit in terms of improved disease-free and
disease-specific survival. However, the improved accuracy
comes with an increased workload for pathology depart-
ments and an increased risk of cancellation of the SNB
procedure on the day of surgery, which in turn has a neg-
ative impact on nodal relapse-free survival. These data
would suggest evaluating the true effectiveness of SPECT/
CT imaging in SNB staging of melanoma is complex and
merits further investigation.
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